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To determine whether human herpesvirus 8 (HHV-8) 
is associated with schistosomal and hepatitis C virus in-
fections in Egypt, we surveyed 965 rural household par-
ticipants who had been tested for HHV-8 and schistosomal 
infection (seroprevalence 14.2% and 68.6%, respectively, 
among those <15 years of age, and 24.2% and 72.8%, re-
spectively, among those ≥15 years of age. Among adults, 
HHV-8 seropositivity was associated with higher age, lower 
education, dental treatment, tattoos, >10 lifetime injections, 
and hepatitis C virus seropositivity. In adjusted analyses, 
HHV-8 seropositivity was associated with dental treatment 
among men (odds ratio [OR] 2.4, 95% conﬁ  dence interval 
[CI] 1.1–5.2) and hepatitis C virus seropositivity among 
women (OR 3.3, 95% CI 1.4–7.9). HHV-8 association with 
antischistosomal antibodies was not signiﬁ  cant for men (OR 
2.1, 95% CI 0.3–16.4), but marginal for women (OR 1.5, 
95% CI 1.0–2.5). Our ﬁ  ndings suggest salivary and possible 
nosocomial HHV-8 transmission in rural Egypt. 
H
uman herpesvirus 8 (HHV-8, also called Kaposi sar-
coma [KS]–associated herpesvirus) is the infectious 
cause of KS (1) and is prevalent in Africa (2). HHV-8 se-
roepidemiology parallels imperfectly KS epidemiology 
(3). Adult HHV-8 seropositivity is very high in eastern and 
central Africa (70%–90%), where KS is endemic, and low-
er in southern and northern Africa (10%–40%), including 
Egypt, where KS is more rare (4). This variation may be 
due, in part, to socioeconomic or environmental factors (5) 
inﬂ  uencing HHV-8 transmission or pathogenesis. HHV-8 
is transmitted through contact with saliva (6–8), but sexual 
(9) and blood-borne (10) transmission also occur.
HHV-8 seroepidemiology in Egypt is incompletely 
described (3,11,12). Egypt offers the opportunity to in-
vestigate how HHV-8 correlates in the general population 
with well-characterized hepatitis C virus (HCV) (13) and 
schistosomal infections (14). Hundreds of thousands of 
Egyptians were exposed to multiple intravenous injections 
during treatment campaigns to control schistosomiasis 
from the 1950s until 1982, which resulted in an epidemic 
of HCV (15). Schistosomal infection has been reported to 
suppress the immune response to HCV, which could lead 
to more persistent infections in those who are co-infect-
ed (16–20). Whether a similar relationship exists with 
HHV-8 is not known. The rarity of KS in Egypt, despite 
its occurrence in organ transplant recipients (21), suggests 
that schistosomal-induced immunosuppression may not 
increase KS risk substantially. We sought to test the hy-
pothesis that schistosomal seropositivity is associated with 
HHV-8 seropositivity, which would support the concept 
that schistosomal-induced immunosuppression modulates 
susceptibility to HHV-8 infection.
Methods
Patient Selection and Serologic Testing for 
HHV-8 and Schistosomal Infections
We randomly selected residual frozen serum samples 
from 965 of ≈6,000 persons who had participated in the 
HCV and schistosomiasis epidemiologic, population–
based, household survey in Assiut Governorate, in rural 
southern Egypt in 1992 (13). Adults and parents of children 
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<15 years of age who had participated in the original survey 
gave informed consent and answered interviewer-adminis-
tered questions about demographics, socioeconomic status, 
medical treatment, and parenteral exposures, including 
injections, transfusions, operations, dental treatment, and 
tattoos. Each participants gave a venous blood sample for 
serologic testing (13). The proportion of children included 
in our study was slightly lower than in the original survey 
because serum samples from some children had been ex-
hausted by tests for HCV and other hepatitis viruses. How-
ever, the included children were otherwise representative 
of the original survey population.
Anti–HHV-8 antibodies were measured by using an 
enzyme immunoassay to K8.1 glycoprotein (a lytic-phase 
antigen) as previously reported (22,23). Antischistosomal 
antibodies were measured by using enzyme-linked immu-
noelectrotransfer blots (EITB) to detect species-speciﬁ  c 
antibodies against microsomal glycoprotein antigens from 
Schistosoma hematobium and S. mansoni (98% sensitivity 
and 99% speciﬁ  city) (24). S. hematobium is the predomi-
nant species causing infection in Assiut Governorate; con-
current or single infection with S. mansoni among local 
inhabitants is rare (14).
Statistical Methods
Because no standard for testing for HHV-8 infection 
exists, we previously based cutoff values for deﬁ  ning se-
ropositivity on visual inspection of the distribution of the 
K8.1 assay optical density (OD) values (10), assuming that 
there are seronegative and seropositive subpopulations. 
However, this approach is subjective. To more objectively 
deﬁ  ne seropositivity, we applied mixture models to the OD 
data (25). Brieﬂ  y, the mixture model was based on the as-
sumption that the OD value for each participant arises from 
either a seronegative or a seropositive subpopulation. The 
formulas and details on parameters for the statistical model 
are described elsewhere ([25]; online Appendix, available 
from www.cdc.gov/EID/content/14/4/586-app.htm). We 
assumed that when the calculated posterior probability of 
seropositivity was >0.5, then the person was seropositive. 
In sensitivity analyses (online Appendix), we used alterna-
tive parameters of the model and also excluded persons with 
an intermediate posterior probability (range: 0.4–0.6).
After deﬁ  ning seropositivity, we used logistic regres-
sion models (PROC GENMOD, SAS 8.0; SAS, Cary, NC, 
USA) to calculate odds ratios (ORs) for HHV-8 associa-
tions with demographic, behavioral, and clinical risk fac-
tors. We used generalized estimation equations that ac-
counted for correlations between persons living in the same 
household to calculate 95% conﬁ  dence intervals (CIs) (26). 
Because HHV-8 seropositivity is age dependent and modes 
of transmission may differ between children and adults, we 
performed univariate and multivariable analyses separately 
for children (<15 years of age) and adults (>15 years of 
age). Because we postulated a priori that antischistosom-
al antibodies were associated with HHV-8, we included 
schistosomal status in all multivariable models. To adjust 
for potential confounding, we included in our multivariable 
models those variables that were associated with HHV-8 
seropositivity at p<0.1 in univariate analyses. Age was ﬁ  t-
ted with a trend whenever this resulted in a statistically sig-
niﬁ  cantly improved model ﬁ  t; otherwise, it was ﬁ  tted as a 
categoric variable with dummy values. Two-tailed p values 
(p<0.05) were considered statistically signiﬁ  cant,  while 
p values between 0.1 and 0.05 were suggestive of a trend.
Results
None of the original household survey participants had 
a history of KS (13). HHV-8 seroprevalence was lower 
among children compared with adults (14.3% vs. 24.2%, 
p<0.001). Among children, in unadjusted analyses, HHV-8 
seroprevalence was higher in girls than boys (20% vs. 9%; 
OR 2.4, 95% CI 1.1–5.3). HHV-8 seroprevalence was not 
signiﬁ  cantly elevated in children with a history of >10 
lifetime injections compared with those with <10 lifetime 
injections (18% vs. 11%, OR 1.8, 95% CI 0.8–3.8) nor 
among those with schistosomal antibodies (16% vs. 10%; 
OR 1.7, 95% CI 0.7–4.3). Age, education, dental treatment, 
tattoos, and HCV antibodies were unrelated to HHV-8 
seropositivity among children. 
Among adult men and women combined, unadjusted 
analyses showed that HHV-8 seropositivity was higher 
among older participants (>45 years of age) compared with 
younger participants (15–24 years of age; OR 4.1, 95% CI 
2.6–6.6); among those currently married (OR 1.9, 95% CI 
1.2–3.0) or divorced, separated, or widowed (OR 3.3, 95% 
CI 1.7–6.4) versus never married; and among those with 
a history of dental treatment (OR 2.1, 95% CI 1.5–2.9), 
>10 lifetime injections (OR 1.5, 95% CI 1.0–2.3), tattoos 
(OR 1.7, 95% CI 1.1–2.7), or HCV seropositivity (OR 1.8, 
95% CI 1.0–3.3) compared with participants without these 
characteristics. Conversely, HHV-8 seropositivity was 
lower among adults who reported primary (OR 0.6, 95% 
CI 0.4–1.0) or higher level of formal education (OR 0.3, 
95% CI 0.2–0.6) compared with participants without for-
mal education.
Antischistosomal antibodies, which indicate past as 
well current infection, were detected among 72.8% of par-
ticipants. Current infection, as indicated by ova in stool or 
urine samples, was noted for 4% of participants, all of whom 
had S. hematobium. S. mansoni was only recently introduced 
in Assiut Governorate and remains rare and focal in distribu-
tion (14). Almost all participants who had S. mansoni an-
tibodies were also positive for S. hematobium. Patterns of 
schistosomal seropositivity differed between women and 
men. Among women, antischistosomal antibody prevalence 
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was inversely related with age (68.8% in those 15–24 years 
of age vs. 34.1% in those >45 years of age; p<0.001); was 
lower in those who were widowed, divorced, or separated 
compared with those who were married or who had never 
married (38.8% vs. 63.4%; p = 0.003); but was unrelated 
to education (p = 0.36) or HCV seropositivity (p = 0 .12). 
Among men, antischistosomal antibody prevalence was un-
related to age (p = 0.61), marital status (p = 0.73), education 
(p = 0.64), or HCV seropositivity (p = 0.12).
In unadjusted sex-speciﬁ  c analyses (Tables 1 and 2), 
HHV-8 seropositivity was not associated with antischisto-
somal antibodies in women (OR 1.0, 95% CI 0.6–1.5); it 
was not signiﬁ  cantly associated in men (OR 2.3, 95% CI 
0.3–19.0), because only 9 men had no antischistosomal an-
tibodies. The HHV-8 associations with age, formal educa-
tion, marital status, and history of dental treatment among 
men and women combined were largely recapitulated in 
the sex-speciﬁ  c analyses, except for associations with hav-
ing tattoos, >10 lifetime injections, and HCV seropositiv-
ity, which were evident in women but not men (Tables 1 
and 2). HHV-8 was signiﬁ  cantly associated with cigarette 
smoking; cigarette smoking was only recorded for men.
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Table 1. Prevalence and crude OR of association of HHV-8 seropositivity with demographic, behavioral, and clinical characteristics
among male patients, Egypt* 
Characteristic n/N % OR 95% CI  p value† 
Total 52/235 22.1 – – –
Age group, y <0.001
   15–24  8/96 8.3 Ref – –
 25–34  16/54 29.6 4.6 2.0–11.0 –
 35–44  10/30 33.3 5.5 1.9–15.7 –
>45 18/55 32.7 5.3 2.2–13.2 –
Education 0.001
 None  19/50 38.0 Ref – –
 Primary  22/100 22.0 0.5 0.2–1.0 –
 Secondary/past  secondary  11/85 12.9 0.2 0.1–0.6 –
Job 0.001
 Student  2/38 5.3 Ref – –
 Not  working  6/31 19.3 4.3 0.8–23.3 –
 Farmer  25/87 28.7 7.3 1.6–32.4 –
  Trade, service, production  13/63 20.6 4.7 1.1–20.0 –
 Technician/secretary  6/16 37.5 10.8 1.9–61.3 –
Marital status 0.004
 Not  married  11/91 12.1 Ref – –
 Married  39/136 28.7 3.1 1.4–6.5 –
 Separated/divorced/widowed  2/8 25.0 7.6 1.0–60.8 –
Dental treatments  <0.001
 No  16/128 12.5 Ref – –
 Yes  36/107 33.6 3.5 1.8–7.1 –
Tattoos 0.53
   No  50/220 22.7 Ref – –
 Present  2/15 13.3 0.5 0.1–2.5 –
HCV serostatus 0.72
 Negative  48/214 22.4 Ref – –
 Positive  4/21 19.0 0.8 0.3–2.5 –
Injections (lifetime)  0.74
 <10  20/72 20.8 Ref – –
>10 37/163 22.7 1.1 0.6–2.1 –
Smoking 0.02
 Never  23/138 16.7 Ref – –
 Ever  29/97 29.9 2.1 1.1–4.0 –
Goza‡ 0.77
 Never  42/193 21.8 Ref – –
 Ever  10/42 23.8 1.1 0.5–2.4 –
Schistosomiasis 0.43
 Negative  1/9 11.1 Ref – –
 Positive  51/226 31.0 2.3 0.3–19.0 –
*OR, odds ratio; HHV-8, human herpesvirus 8; CI, confidence interval; Ref, referrent; HCV, hepatitis C virus. 
†p value for age group and education is test for trend; otherwise, p value is test for heterogeneity 
‡Goza is a method of tobacco smoking in which tobacco smoke passes through a water pipe. Human Herpesvirus 8 Infection, Egypt
In a multivariable analysis, HHV-8 seropositivity was 
higher among girls than boys (OR 2.6, 95% CI 1.2–5.8) 
and marginally associated with antischistosomal antibod-
ies (OR 2.2, 95% CI 0.8–5.6). Among adult men, HHV-8 
seropositivity was independently associated with older age 
and history of dental treatment but not with schistosomal 
antibodies (OR 2.3, 95% CI 0.3–16.1; Table 3). Among 
women, HHV-8 seropositivity was associated with older 
age, HCV seropositivity, and marginally with antischisto-
somal antibodies (OR 1.5, 95% CI 1.0–2.5; p = 0.07).
Discussion
We report HHV-8 seroepidemiology in a rural popula-
tion in Egypt in which correlates of schistosomal and HCV 
were previously characterized (13,14). As in other popula-
tions, HHV-8 seropositivity in Egypt rose with increasing 
age (3,5). In subgroups, we found associations of HHV-8 
seropositivity with history of dental therapy, lifetime injec-
tions, tattoos, and HCV seropositivity.
Previous studies of HHV-8 in Egypt (11,12) reported 
a seroprevalence of ≈40%, which is ≈2× the prevalence we 
observed. Those studies were hospital based, were con-
ducted in urban areas, and detected anti-HHV-8 antibod-
ies with lytic immunoﬂ  uorescence assays; all of these fac-
tors may have contributed to higher prevalence estimates. 
Despite these differences, the patterns in our associations 
support their validity. First, we detected HHV-8 antibodies 
in children, consistent with earlier reports and nonsexual 
HHV-8 spread in Egypt (11). Second, HHV-8 seropreva-
lence increased with age, in accord with the general pattern 
of HHV-8 observed in other populations (5). Among men, 
HHV-8 seropositivity was signiﬁ   cantly associated with 
dental treatment, which may be a marker for transmission 
through saliva- or blood-contaminated dental instruments. 
Our HHV-8 associations with a history of >10 lifetime in-
jections, tattoos, and HCV seropositivity also point to pos-
sible blood-borne transmission and agree with other studies 
(10,27,28). Sexual transmission might be suggested by our 
HHV-8 association with marital status, but this association 
did not persist after adjustment for age. Rather than ongo-
ing transmission among adults, higher HHV-8 seropositiv-
ity in older persons may be due to a birth-cohort effect, 
i.e., reﬂ  ecting periods of elevated HHV-8 transmission risk 
in the past. In this regard, the widespread use of intrave-
nous injections for schistosomiasis treatment and control 
programs from 1950 to 1982 would be consistent with a 
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Table 2. Prevalence and crude OR of association of HHV-8 seropositivity with demographic, behavioral, and clinical characteristics
among female patients, Egypt* 
Characteristic n/N % OR 95% CI  p value† 
Total 125/495 25.3 – – –
Age group, y <0.001
 15–24  23/148 15.5 Ref – –
 25–34  21/106 19.8 1.4 0.7–2.7 –
 35–44  31/115 27.0 2.0 1.1–3.6 –
>45 50/126 39.7 3.6 2.1–6.3 –
Education <0.001
 None  88/307 28.7 Ref – –
 Primary  34/154 32.7 0.7 0.4–1.1 –
 Secondary/past  secondary  4/38 22.5 0.3 0.1–0.8 –
Job 0.11
 Other‡  2/21 9.5 Ref – –
 Housewife  121/470 25.7 3.3 0.8–14.3 –
Dental treatments  0.02
 No  49/239 20.5 Ref – –
 Yes  77/260 29.6 1.6 1.1–2.5 –
Tattoos 0.006
 No  93/410 22.7 Ref – –
 Present  33/89 37.1 2.0 1.2–3.3 –
HCV serostatus 0.006
 Negative  112/470 23.8 Ref – –
 Positive  14/29 48.3 3.0 1.4–6.5 –
Injections (lifetime)  0.03
 <10  23/128 18.0 Ref – –
>10 103/371 27.8 1.7 1.1–2.9 –
Schistosomiasis 0.94
 Negative  48/189 25.4 Ref – –
 Positive  76/303 25.1 1.0 0.6–1.5 –
*OR, odds ratio; HHV-8, human herpesvirus 8; CI, confidence interval; Ref, referrent; HCV, hepatitis C virus. 
†p value for age group and education is test for trend; otherwise, p value is test for heterogeneity. 
‡Job category for women: “Other” includes women who are students, are not working, or have technical or scientific jobs. RESEARCH
birth-cohort effect for high HHV-8 seroprevalence among 
our older participants. However, most populations, includ-
ing those with no similar historical programs, have higher 
HHV-8 seroprevalence among older persons, which sug-
gests that ongoing HHV-8 transmission among adults is a 
more likely explanation.
We found a 2-fold higher HHV-8 seroprevalence in 
persons who also had schistosomal antibodies. In multi-
variable analyses, the CI for this association was 1.0–2.5 
among women, but it was wide among children (0.8–5.6) 
and especially among men (0.3–16.1). Chance association 
and serologic cross-reactivity between HHV-8 and schis-
tosomal antibodies are possible explanations, but schis-
tosomal antibodies may be a valid marker for exposure 
to injections in the historical anti-schistosomal program; 
these  ﬁ   ndings are consistent with parenteral transmis-
sion of HHV-8 as discussed above. Another possibility 
is that anti-schistosomal antibodies may be a marker for 
contact with surface water sources or walking barefoot, 
which are also risk factors for HHV-8 seropositivity and 
KS (5,7,29). No biologic explanation has been advanced 
for these environmental correlations with HHV-8 and KS. 
Our study suggests that perhaps contact with surface wa-
ter or walking barefoot is a marker of exposure to and po-
tential infection with Schistosoma or other water-related 
parasites. Infection with such parasites could inﬂ  uence 
the natural history of HHV-8 by shifting the immune re-
sponse from  a T helper 1 (Th1)–type response, which is 
central to controlling viral infections, to a Th2-dominant 
response (30), which is less effective against viral infec-
tions. If this model is correct, schistosomal infection could 
increase susceptibility to HHV-8 infection at relatively 
low exposure to the virus. In parallel, Th2-dominant hosts 
may fail to effectively control HHV-8 infection and thus 
shed infectious virions in saliva more frequently and at 
higher levels, resulting in higher HHV-8 transmission. If 
our ﬁ  ndings are conﬁ  rmed, they could drive investigations 
of environmental characteristics, including exposures to 
volcanic soil or plants (31), to explain variation in HHV-8 
infection and possibly KS.
Our study has several limitations. First, current HHV-8 
serologic assays have imperfect speciﬁ  city and sensitivity 
(32), which could have contributed to the lower HHV-8 
seroprevalence observed. Except for the possible cross-
reactivity mentioned above, serologic misclassiﬁ  cation is 
likely to be random, which would attenuate associations to-
ward the null. Second, our HCV and schistosomal antibody 
assays cannot distinguish current from resolved infections, 
diminishing the strength of observed associations as well. 
Third, with our cross-sectional design, we cannot deter-
mine the temporality of associations. This limitation may 
be particularly relevant to our ﬁ  ndings of HHV-8 with an-
tischistosomal antibodies. The antischistosomal programs 
surely reduced the prevalence and load of schistosoma 
eggs, but they may also have contributed to HHV-8 trans-
mission through injections. Finally, we studied only ≈15% 
of the participants in the original survey, which limited our 
statistical power to estimate some associations. 
The strengths of our study include our state-of-the-
art serologic methods, our model-based approach to esti-
mating infection risk, and our well-characterized general 
population with detailed socioeconomic and clinical data.
HHV-8 seropositivity was associated with older age, dental 
therapy, lifetime injections, and HCV and schistosomiasis 
seropositivity. These ﬁ   ndings suggest salivary and pos-
sible nosocomial HHV-8 transmission in rural Egypt and 
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Table 3. Adjusted OR of association of HHV-8 seropositivity with demographic and clinical variables among adults, Egypt* 
Men Women
Characteristic OR 95% CI  p value  OR 95% CI  p value 
Age group, y† 0.002
 15–24  Ref – – Ref. – –
 25–34  1.6 1.2–2.2 – 0.8 0.4–1.6 0.53
 35–44  2.6 1.4–4.9 – 1.5 0.8–2.9 0.15
>45 4.3 1.7–11.0 – 3.1 1.5–6.4 <0.001
Dental treatments‡ 0.04
No Ref – – – – –
Yes 2.3 1.1–4.9 – – – –
HCV serostatus‡  – 0.007
Negative – – – Ref – –
Positive – – – 3.3 1.4–7.9 –
Schistosomiasis§ 0.47 0.07
 Negative  Ref – – Ref – –
 Positive  2.3 0.3–16.1 – 1.5 1.0–2.5 –
*OR, odds ratio; HHV-8, human herpesvirus 8; CI, confidence interval; Ref, referrent; HCV, hepatitis C virus. 
†p value is for age group fitted with trend among men; p values for heterogeneity for categories given for women (see Statistical Methods). 
‡Missing values in sex-specific analyses mean the variable was not significant and was excluded from final multivariable model.
§Schistosomiasis seropositivity was included in models even when not significant because we hypothesized a priori that it was associated with HHV-8
seropositivity (see online Appendix, available from www.cdc.gov/EID/content/14/4/586-app.htm). Human Herpesvirus 8 Infection, Egypt
a potential biologic explanation for geographic variation of 
HHV-8 seropositivity and KS.
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